IN8bio【INAB】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.2831

買値

0.2845

売値

0.2939

出来高

271,148

0.2803 日の範囲 0.3051

0.217 52 週間の範囲 2.48

時価総額

20.52M

前日終値

0.2906

始値

0.2922

時刻

1138

0.2831

(formt)

最終取引時間

財務取引量

US$ 78,282

VWAP

0.288706

平均取引量 (3 か月)

1,240,885

発行済株式数

72,483,253

配当利回り

PER

-0.70

1 株当たり利益 (EPS)

-0.41

歳入

純利益

-30.01M

IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.in8bio.com

本社

Wilmington, Delaware, USA

設立

IN8bio Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker INAB. The last closing price for IN8bio was US$0.29. Over the last year, IN8bio shares have traded in a share price range of US$ 0.217 to US$ 2.48.

IN8bio currently has 72,483,253 shares in issue. The market capitalisation of IN8bio is US$21.06 million. IN8bio has a price to earnings ratio (PE ratio) of -0.70.

Form 8-K - Current report

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median...

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that...

Form 8-K - Current report

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median overall survival (OS) from standard-of-care Stupp regimen while none of the patients...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0281	-9.02956298201	0.3112	0.36	0.2819	614202	0.31317976	CS
4	-0.053	-15.7691163344	0.3361	0.41	0.2819	675800	0.33324428	CS
12	-0.038	-11.8343195266	0.3211	0.5566	0.217	1240885	0.38066067	CS
26	-1.2369	-81.375	1.52	1.74	0.217	803233	0.51231146	CS
52	-1.1169	-79.7785714286	1.4	2.48	0.217	568036	0.74252931	CS
156	-6.3169	-95.7106060606	6.6	6.79	0.217	683068	2.06627022	CS
260	-9.7169	-97.169	10	10.319	0.217	612822	2.12103331	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
WKEYWISeKey International Holdings AG	US$ 7.84 (139.02%)	75.53M
IPHAInnate Pharma SA	US$ 3.00 (93.55%)	13.59M
AVLDirexion Daily AVGO Bull 2X Shares	US$ 33.67 (48.92%)	658.55k
LOOPLoop Industries Inc	US$ 1.8092 (47.09%)	82.56M
AVGXDefiance Daily Target 2X Long AVGO ETF	US$ 31.49 (46.67%)	3.55M
RPTXRepare Therapeutics Inc	US$ 1.765 (-55.54%)	4.7M
INOInovio Pharmaceuticals Inc New	US$ 2.31 (-38.56%)	9.86M
XXII22nd Century Group Inc	US$ 0.048 (-34.69%)	42.23M
FLGCFlora Growth Corporation	US$ 1.30 (-34.34%)	4.14M
WTOUTime Limited	US$ 0.281 (-32.74%)	3.79M
NVDANVIDIA Corporation	US$ 134.25 (-2.25%)	231.23M
SOUNSoundHound AI Inc	US$ 16.905 (23.66%)	159.56M
TRUGTruGolf Holdings Inc	US$ 0.6794 (30.93%)	141.89M
RGTIRigetti Computing Inc	US$ 7.155 (19.85%)	124.45M
AVGOBroadcom Inc	US$ 224.80 (24.43%)	121.33M